NSPR (InspireMD) ROCE %: -105.77% (As of Mar. 2026)

What is InspireMD ROCE %?

InspireMD NSPR -0.01% 35 ROCE % is -105.77% as of Mar. 2026. GuruFocus rates NSPR with a GF Score™ of 35/100 and a GF Value™ of $1.78 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InspireMD's annualized ROCE % for the quarter that ended in Mar. 2026 was -105.77%.

InspireMD (NAS:NSPR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InspireMD ROCE % Related Terms

InspireMD ROCE % Historical Data

* Premium members only.

The historical data trend for InspireMD's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD ROCE % Chart

InspireMD Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-59.53

-68.11

-69.09

-82.98

-101.44

InspireMD Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-130.16	-187.39	-113.57	-76.51	-105.77

35GF Score

InspireMD Inc NSPR

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InspireMD ROCE % Calculation

InspireMD's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-49.614	/	( ( (46.807 - 7.678)	+	(69.404 - 10.712) )	/ 2 )
	=	-49.614	/	( (39.129	+	58.692)	/ 2 )
	=	-49.614	/	48.9105
	=	-101.44 %

InspireMD's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-55.912	/	( ( (69.404 - 10.712)	+	(56.471 - 9.443) )	/ 2 )
	=	-55.912	/	( ( 58.692	+	47.028 )	/ 2 )
	=	-55.912	/	52.86
	=	-105.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -105.77% mean?

InspireMD (NSPR) has a ROCE % of -105.77% as of Mar. 2026.

Is InspireMD's ROCE % too high?

InspireMD's current ROCE % is -105.77%. Overall, InspireMD has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does InspireMD's ROCE % compare to TELA and MYO?

InspireMD's ROCE % of -105.77% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current ROCE % is -105.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InspireMD stock overvalued right now?

Based on GuruFocus' analysis, InspireMD (NSPR) is currently considered Possible Value Trap. The stock's GF Value™ is $1.78, compared to a current price of $0.70 — trading 60.7% below its estimated fair value. The current ROCE % is -105.77%. InspireMD's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For InspireMD (NSPR), the current ROCE % is -105.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (NSPR) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of $0.70 is trading 60.7% below its estimated GF Value™ of $1.78. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for NSPR:

ROCE %: -105.77%
GF Value™: $1.78 vs. price of $0.70 (60.7% below fair value)
GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the NSPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TELA MYO PAVM NSYS ARAY BDMD FOFA SRTS ELUT RDGL ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges II2:Germany

Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126

Website https://www.inspiremd.com

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

35GF Score

Get the complete analysis for NSPR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70

Price

$1.78

GF Value

View NSPR Analysis

See ROCE % data for all stocks →